Project Description
Giving Emphysema Patients Some Breathing Space
InterVapor® or BTVA is the only vapor-based therapy that enables controlled, precise, rapid abalation of emphysemic lung tissue. It stands apart from all other treatment methods in important—and exclusive—ways. the first personalized treatment for emphysema that allows targeted treatment of a patients’ most diseased emphysema segments while sparing healthier segments from being unnecessarily reduced.
InterVapor Targeted Vapor Therapy has been proven to provide effective lung volume reduction1 for both CV+ and CV- patients.2 With repeat procedures staged over time, physicians can make breathing more efficient, and maintain improvements in quality of life over the course of the disease.
Making Progressive Breathlessness Less Progressive
As the targeted vapor ablates unhealthy tissue from the more diseased segments of the lungs (shown in pink), new space is created for the healthier sections to expand (shown in green), allowing more air to flow in and out of the lungs.
NOVATECH® GSS™ Tracheobronchial silicone stents
Indications:
Maintaining airway patency after desobstruction or dilatation of a stenosis, in particular in the following cases:
- Tracheobronchial tumors
- Tracheobronchial stenoses with scarring
- Tracheobronchial stenoses after anastomosis, resection or lung transplantation
- Diameter reduction from intraluminal, extraluminal and intramural changes
